Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Second Quarter (Q2) and First Half (H1) ended 30 June 2006
Announcement Date: 26 July 2006
GSK reported strong financial performance driven by a 10% growth in pharmaceutical sales, primarily fueled by US market expansion and the launch of new products. The company raised its full-year 2006 earnings guidance.
Key Financial Metrics
| Metric | Q2 2006 (£m) | Q2 2005 (£m) | CER Growth % | H1 2006 (£m) | H1 2005 (£m) | CER Growth % |
|---|---|---|---|---|---|---|
| Turnover | 5,811 | 5,246 | 9% | 11,624 | 10,282 | 9% |
| Operating Profit | 1,911 | 1,711 | 13% | 4,085 | 3,458 | 14% |
| Profit Before Tax | 1,897 | 1,662 | 15% | 4,067 | 3,373 | 16% |
| Profit After Tax | 1,337 | 1,189 | 14% | 2,867 | 2,412 | 15% |
| Earnings Per Share (EPS) | 23.3p | 20.4p | 15% | 49.8p | 41.5p | 16% |
| Operating Margin | 32.9% | 32.6% | - | 35.1% | 33.6% | - |
Cash Flow & Liquidity:
- Net Cash Inflow from Operating Activities (Q2): £1,122 million.
- Cash and Cash Equivalents (30 June 2006): £3,782 million.
- Net Debt (30 June 2006): £655 million (reduced from £1,237 million at year-end 2005).
- Share Buy-backs (Q2): £293 million repurchased; total expected for 2006 is £1 billion.
- Dividend: Second interim dividend declared at 11 pence per share (vs. 10 pence in Q2 2005).
Material Changes vs. Prior Period
- Pharmaceutical Sales: Rose 10% to £5.0 billion. US sales grew 18% (reported) to £2.6 billion, driven by wholesaler stocking of Avandia/Avandamet. Underlying US growth estimated at 12%.
- Key Product Performance:
- Seretide/Advair: +12% to £822 million.
- Avandia Family: +32% to £477 million (US re-supply and new indications).
- Vaccines: +17% to £387 million (US +35%).
- Flonase: -53% to £68 million due to generic competition in the US.
- Consumer Healthcare: Sales up 5% to £790 million. Sensodyne (+25%) and Lucozade (+18%) drove growth, offsetting declines in Aquafresh and Ribena.
- Cost Structure: R&D expenditure increased to 14.7% of sales (from 13.4%). SG&A grew 8% (2% excluding legal costs).
Guidance, Outlook, and Risks
Guidance Update: GSK raised its full-year 2006 earnings guidance to approximately 12% EPS growth in Constant Exchange Rate (CER) terms, up from the previous guidance of around 10%.
Pipeline Highlights:
- H5N1 Vaccine: Headline data showed >80% immune response at low doses; filing expected before year-end.
- Tykerb: Positive breast cancer data; US filing planned for Q3 2006.
- Cervarix: New data reinforces adjuvant advantage; US filing by year-end.
- Discontinuation: Development of radafaxine (depression) discontinued due to unfavorable risk/benefit assessment.
Risks and Contingencies:
- Tax Disputes: Significant ongoing dispute with the US IRS regarding transfer pricing for heritage products. Total claims for 1989-2000 amount to $8.6 billion (tax + interest). Trial delayed to January 2007; decision expected in H2 2008.
- Legal Provisions: Aggregate provision for legal and other disputes (excluding tax) was over £1.2 billion as of 30 June 2006.
- Patent Litigation: Active infringement cases regarding Imitrex, Wellbutrin XL, Zofran, and Requip.
Investor Verification Checklist
- US Tax Liability: Verify the status of the IRS transfer pricing dispute and the adequacy of the £2.3 billion tax creditor balance provision.
- Generic Impact: Monitor the trajectory of sales for Flonase, Lamictal, and Zofran as generic competition intensifies in Europe and the US.
- Pipeline Execution: Confirm regulatory filing dates for Tykerb, Cervarix, and the H5N1 vaccine to validate the raised earnings guidance.
- Share Buy-backs: Track the execution of the remaining £707 million of the £1 billion annual buy-back program.
- Avandia Safety: Review ongoing safety data and regulatory stance on Avandia/Avandamet, given their significant contribution to revenue growth.